

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

<i>COMPLETE IF KNOWN</i>	
Application Number	10/537,476
Filing Date	June 3, 2005
First Named Inventor	Joseph L. Duffy, et al.
Group Art Unit	1626
Examiner Name	M. Barker
Attorney Docket Number	21288YP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
8	PCT	WO 03/082817 A2			MERCK & CO., INC.	10/09/2003
9	PCT	WO 03/000180 A2			MERCK & CO., INC.	01/03/2003
10	PCT	WO 03/000181 A2			MERCK & CO., INC.	01/03/2003
11	PCT	WO 03/000181 A3			MERCK & CO., INC.	01/03/2003
12	PCT	WO 02/076450 A1			MERCK & CO., INC.	10/03/2002
13	PCT	WO 2004/007468 A1			MERCK & CO., INC.	01/22/2004
14	PCT	WO 2004/032836 A2			MERCK & CO., INC.	04/22/2004
15	PCT	WO 2004/050022 A2			MERCK & CO., INC.	06/17/2004
16	PCT	WO 2004/058266 A1			MERCK & CO., INC.	07/15/2004
17	PCT	WO 2004/064778 A2			MERCK & CO., INC.	08/05/2004

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Meck & Co., Inc. -7/12/2005

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

STATEMENT OF APPALIC
AUG 29 2005
(use as many sheets as necessary)

Sheet

of

Attorney Docket Number

COMPLETE IF KNOWN

Application Number	10/537,476
Filing Date	June 3, 2005
First Named Inventor	Joseph L. Duffy, et al.
Group Art Unit	1626
Examiner Name	M. Barker
Attorney Docket Number	21288YP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
18	PCT	WO 2004/069162 A2			MERCK & CO., INC.	08/19/2004
19	PCT	WO 02/02560 A2			NOVO NORDISK A/S	01/10/2002
20	PCT	WO 01/96295 A2			NOVARTIS AG	12/20/2001
21	PCT	WO 01/96295 A3			NOVARTIS AG	12/20/2001
22	PCT	WO 01/34594 A1			Guilford Pharmaceuticals, Inc.	05/17/2001
23	PCT	WO 00/34241			NOVARTIS AG	06/15/2000
24	PCT	WO 98/19998 A2			NOVARTIS AG	05/14/1998
25	PCT	WO 98/19998 A3			NOVARTIS AG	05/14/1998
26	PCT	WO 97/40832			Hansknoll-Institut Fur Naturstoff-Forschung E.V.	11/06/1997
27	PCT	WO 03/000180 A3			MERCK & CO., INC.	01/03/2003

**Examiner
Signature**

/Michael Barker/

Date Considered

07/10/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2005

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

STATEMENT BY APPLICANT

AUG 29 2005 (181)

PATENT *Please use as many sheets as necessary*)

<i>COMPLETE IF KNOWN</i>	
Application Number	10/537,476
Filing Date	June 3, 2005
First Named Inventor	Joseph L. Duffy, et al.
Group Art Unit	1626
Examiner Name	M. Barker
Attorney Docket Number	21288YP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
28	PCT	WO 02/02560		A3	NOVO NORDISK	01/10/2002
29	PCT	WO 01/42262			AKZO NOBEL N.V.	06/14/2001
30	PCT	WO 2004/043940			MERCK & CO., INC.	05/27/2004
31	PCT	WO 2004/007468			MERCK & CO., INC.	01/22/2004
32	PCT	WO 2004/110436			MERCK & CO., INC.	12/23/2004
33	PCT	WO 2004/112701		A2	MERCK & CO., INC.	12/29/2004
34	PCT	WO 2004/112701		A3	MERCK & CO., INC.	12/29/2004
35	PCT	WO 2005/011581		A2	MERCK & CO., INC.	02/10/2005
36	PCT	WO 2005/044195		A2	MERCK & CO., INC.	05/19/2005
37	PCT	WO 2005/002530		A2	SMITHKLINE BEECHAM CORP.	01/09/2003

**Examiner
Signature**

/Michael Barker/

Date Considered


07/10/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. - 7/12/2005

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**



AUG 29 2005

(use as many sheets as necessary)

Sheet

of

4

COMPLETE IF KNOWN	
Application Number	10/537,476
Filing Date	June 3, 2005
First Named Inventor	Joseph L. Duffy, et al.
Group Art Unit	1626
Examiner Name	M. Barker
Attorney Docket Number	21288YP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
38	J. J. Holst, "Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors", Expert Opin. Emerg. Drugs, Vol. 9(1) pp. 155-166, 2004.	
39	C. F. Deacon, et al., "Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?", Expert Opin. Investig. Drugs, Vol. 13(9) pp. 1091-1102, 2004.	
40	K. Augustyns et al., "Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes", Expert Opin. Ther. Patents, Vol. 13(4), pp. 499-510, 2003.	
41	Novartis AG: WO0034241, "Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus", Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1937-1942, 2000.	
42	O. J. Orucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Exp. Opin Invest. Drugs, Vol. 12, 2004, pages 87-100.	
43	T. P. Vahl & D. A. D'Alessio, "Gut peptides in the treatment of diabetes mellitus" Exp. Opin. Invest. Drugs, Vol. 13, 2004, pages 177-188.	
44	L. B. Knudsen, "Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes", J. Med. Chem., Vol. 47, 2004, pages 4128-4134.	
45	Ann E. Weber, "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem., Vol. 47, 2004, pages 4135-4141.	
46	I. J. Holst and C. F. Deacon, "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Curr. Opin Pharmacology, Vol. 4, 2004, pages 589-596.	
47	C. F. Deacon, "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, Sept. 2004, pages 2181-2189.	

Examiner Signature

/Michael Barker/

Date Considered

07/10/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2005